Correspondence | Open

This is an unedited manuscript that has been accepted for publication. Nature Research are providing this early version of the manuscript as a service to our customers. The manuscript will undergo copyediting, typesetting and a proof review before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma


  1. 1.

    Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL, et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood. 2013;121:1604–11.

  2. 2.

    Green MR, Kihira S, Liu CL, Nair RV, Salari R, Gentles AJ, et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci USA. 2015;112:E1116–1125.

  3. 3.

    Kridel R, Chan FC, Mottok A, Boyle M, Farinha P, Tan K, et al. Histological transformation and progression in follicular lymphoma: a clonal evolution study. PLoS Med. 2016;13:e1002197.

  4. 4.

    Li H, Kaminski MS, Li Y, Yildiz M, Ouillette P, Jones S, et al. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood. 2014;123:1487–98.

  5. 5.

    Okosun J, Bödör C, Wang J, Araf S, Yang CY, Pan C, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46:176–81.

  6. 6.

    Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, et al. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet. 2016;48:183–8.

  7. 7.

    Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes AB, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6:130–40.

  8. 8.

    Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.

  9. 9.

    Makohon-Moore AP, Zhang M, Reiter JG, Bozic I, Allen B, Kundu D, et al. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet. 2017;49:358–66.

  10. 10.

    Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111–22.

  11. 11.

    Jiang Y, Ortega-Molina A, Geng H, Ying HY, Hatzi K, Parsa S, et al. CREBBP inactivation promotes the development of HDAC3-dependent lymphomas. Cancer Discov. 2017;7:38–53.

  12. 12.

    Zhang J, Vlasevska S, Wells VA, Nataraj S, Holmes AB, Duval R, et al. The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma. Cancer Discov. 2017;7:322–37.

  13. 13.

    Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C, et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat Med. 2015;21:1199–208.

  14. 14.

    Zhang J, Dominguez-Sola D, Hussein S, Lee JE, Holmes AB, Bansal M, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med. 2015;21:1190–8.

  15. 15.

    Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017;376:2109–21.

Download references


We are indebted to the patients for donating tumor specimens as part of this study. The authors thank the Centre de Ressources Biologiques (CRB)-Santé of Rennes (BB-0033-00056) for patient samples, Queen Mary University of London Genome Centre for Illumina Miseq sequencing, and the support by the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London for Illumina Hiseq sequencing. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. This work was supported by grants from the Kay Kendall Leukaemia Fund (KKL 757 awarded to J.O.), Cancer Research UK (22742 awarded to J.O., 15968 awarded to J.F., Clinical Research Fellowship awarded to S.A.), Bloodwise through funding of the Precision Medicine for Aggressive Lymphoma (PMAL) consortium, Centre for Genomic Health, Queen Mary University of London, Carte d’Identité des Tumeurs (CIT), Ligue National contre le Cancer, Pôle de biologie hospital universitaire de Rennes, CRB-Santé of Rennes (BB-0033-00056), and CeVi/Carnot program.

Author contributions

J.O. conceived the study; S.A., J.F., J.W., and J.O. designed the study; S.A., J.W., K.K., J.F., and J.O. wrote the manuscript; C.P., J.K.D., P.J., S.M., R.A., J.G.G., and T.G. identified patients for the study and collected clinical information; E.K., S.I., and A.C. prepared DNA samples; M.C. performed pathological review of specimens; J.W., C.C., and T.G. performed the bioinformatic analysis; S.A., K.K., C.P., E.K., T.R., A.R.-M., and J.H. performed experiments; S.A., J.W., K.K., E.K., T.R., J.H., A.R.-M, and J.O. analyzed the data. All authors read, critically reviewed, and approved the manuscript.

Author information

Author notes


    1. Centre for Haemato-Oncology, Barts Cancer Institute, London, UK

      • Shamzah Araf
      • , Koorosh Korfi
      • , Eleni Kotsiou
      • , Ana Rio-Machin
      • , Tahrima Rahim
      • , James Heward
      • , Andrew Clear
      • , Sameena Iqbal
      • , Jeff K. Davies
      • , Maria Calaminici
      • , Silvia Montoto
      • , Rebecca Auer
      • , John G. Gribben
      • , Jude Fitzgibbon
      •  & Jessica Okosun
    2. Centre for Genomic Health, Queen Mary University of London, London, UK

      • Shamzah Araf
    3. Centre for Molecular Oncology, Barts Cancer Institute, London, UK

      • Jun Wang
      •  & Claude Chelala
    4. UMR INSERM 1236, Université de Rennes, 1, EFS de Bretagne, CHU de Rennes, Rennes, France

      • Celine Pangault
      •  & Thierry Fest
    5. Cancer Sciences Unit, Cancer Research UK Centre, Southampton, UK

      • Peter Johnson
    6. Evolution and Cancer Laboratory, Barts Cancer Institute, London, UK

      • Trevor Graham


    1. Search for Shamzah Araf in:

    2. Search for Jun Wang in:

    3. Search for Koorosh Korfi in:

    4. Search for Celine Pangault in:

    5. Search for Eleni Kotsiou in:

    6. Search for Ana Rio-Machin in:

    7. Search for Tahrima Rahim in:

    8. Search for James Heward in:

    9. Search for Andrew Clear in:

    10. Search for Sameena Iqbal in:

    11. Search for Jeff K. Davies in:

    12. Search for Peter Johnson in:

    13. Search for Maria Calaminici in:

    14. Search for Silvia Montoto in:

    15. Search for Rebecca Auer in:

    16. Search for Claude Chelala in:

    17. Search for John G. Gribben in:

    18. Search for Trevor Graham in:

    19. Search for Thierry Fest in:

    20. Search for Jude Fitzgibbon in:

    21. Search for Jessica Okosun in:

    Conflict of interest

    The authors declare that they have no conflict of interest

    Corresponding authors

    Correspondence to Shamzah Araf or Jessica Okosun.

    Electronic supplementary material

    Creative Commons BY-NC-SA

    Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. If you remix, transform, or build upon this article or a part thereof, you must distribute your contributions under the same license as the original. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit